Lite Strategy, Inc.
LITSHealthcare|Biotechnology|US
$1.02
+0.05 (+4.93%)
DCF Value
$0.16
Tangible Book / Share
$1.71
Cash / Share
$0.13
About
Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.
Stock Price
-44.6%(1Y)
1M
-16.4%
3M
+12.4%
6M
-16.4%
YTD
-22.7%
1Y
-54.9%
3Y
-77.5%
5Y
-77.5%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$31.0M
Employees4 (-86% YoY)
CEOJustin J. File
IPO DateDec 18, 2003
Beta0.04
52-Week Range$0.6888 – $2.26
Avg Volume401,534
ExchangeNASDAQ
Websitelitestrategy.com
Ownership
Float77.6%
Shares Outstanding30.4M
Recent Insider Trades
Glover NicholasAWARD
Oct 22, 2026100,000 shares @ $1.19
Glover NicholasBUY
Jul 23, 20251,000 shares @ $6.00
Glover NicholasBUY
Jul 22, 20251,000 shares @ $6.55
File Justin J.AWARD
Oct 22, 2026600,000 shares @ $1.19
DRISCOLL FREDERICK WAWARD
Oct 22, 2026100,000 shares @ $1.19
Peers
Recent News
Litecoin Just Turned 15. Has It Kept Up With Bitcoin?
Oct 17, 2026 · 247wallst.com
Lite Strategy Marks 15 Years of Litecoin with Launch of "Proof of Time" Public Industry Archive
Oct 13, 2026 · globenewswire.com
Stock Traders Purchase High Volume of Lite Strategy Call Options (NASDAQ:LITS)
Oct 3, 2026 · defenseworld.net
Lite Strategy Reports Fiscal Year 2026 Financial Results
Sep 29, 2026 · globenewswire.com
Lite Strategy to Present at the 28th Annual H.C. Wainwright Global Investment Conference in New York
Sep 10, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:19 AM